RxDoctor Payments Data

Jennifer Rizzo

Psychiatric/Mental Health · Getzville, NYNPI 1497415467

Payments from drug & device makers

$1,436in general payments, 2019–2025

Across 64 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$653
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$587
  • Teva Pharmaceuticals USA, Inc.$125
  • Lundbeck LLC$48
  • Takeda Pharmaceuticals U.S.A., Inc.$23

What the payments were for

  • Food & beverage$1,436100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,436 in reported general payments places this provider in the 70th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$4,179
Medicare patients
14
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$104,650
VraylarCariprazine Hcl23$36,372
CaplytaLumateperone Tosylate18$30,759
Lurasidone Hcl21$11,595
VyvanseLisdexamfetamine Dimesylate11$3,779
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine31$1,853
Ziprasidone Hcl14$1,476
Aripiprazole54$1,458
Bupropion XlBupropion Hcl40$1,155
Quetiapine Fumarate ErQuetiapine Fumarate16$977
Duloxetine Hcl36$921
Alprazolam38$906
Fluvoxamine Maleate21$727
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine31$717
Perphenazine27$673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$653$36,37223 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$587$30,75918 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$23$3,77911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Getzville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →